Report cover image

Chronic Myelogenous Leukemia Therapeutics Market by Tyrosine Kinase Inhibitors (Antimetabolites, Asciminib, Bosutinib), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2023-2030

Publisher 360iResearch
Published Oct 05, 2023
Length 188 Pages
SKU # IRE18314001

Description

Chronic Myelogenous Leukemia Therapeutics Market by Tyrosine Kinase Inhibitors (Antimetabolites, Asciminib, Bosutinib), Distribution Channel (Hospital Pharmacies, Online Pharmacies, Retail Pharmacies) - Global Forecast 2023-2030


The Chronic Myelogenous Leukemia Therapeutics Market is projected to reach USD 12.95 billion by 2030 from USD 7.19 billion in 2022, at a CAGR of 7.63% during the forecast period.

Market Segmentation & Coverage:

This research report analyzes various sub-markets, forecasts revenues, and examines emerging trends in each category to provide a comprehensive outlook on the Chronic Myelogenous Leukemia Therapeutics Market.
  • Based on Tyrosine Kinase Inhibitors, market is studied across Antimetabolites, Asciminib, Bosutinib, Dasatinib, Nilotinib, and Ponatinib. The Asciminib is projected to witness significant market share during forecast period.
  • Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies. The Hospital Pharmacies is projected to witness significant market share during forecast period.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Europe, Middle East & Africa is projected to witness significant market share during forecast period.
Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is an indispensable tool for assessing the Chronic Myelogenous Leukemia Therapeutics Market. It comprehensively evaluates vendors, analyzing key metrics related to Business Strategy and Product Satisfaction. This enables users to make informed decisions tailored to their specific needs. Through advanced analysis, vendors are categorized into four distinct quadrants, each representing a different level of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V). Be assured that this insightful framework empowers decision-makers to navigate the market with confidence.

Market Share Analysis:

The Market Share Analysis offers invaluable insights into the vendor landscape Chronic Myelogenous Leukemia Therapeutics Market. By evaluating their impact on overall revenue, customer base, and other key metrics, we provide companies with a comprehensive understanding of their performance and the competitive environment they confront. This analysis also uncovers the level of competition in terms of market share acquisition, fragmentation, dominance, and industry consolidation during the study period.

Key Company Profiles:

The report delves into recent significant developments in the Chronic Myelogenous Leukemia Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbvie Inc., Amneal Pharmaceuticals LLC, Bristol Myers Squibb Company, F. Hoffmann La Roche Ltd., Ilyang Pharmaceutical Co. Ltd., Incyte Corporation, Innovent Biologics Inc., Lupin Ltd., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Co. Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

The report offers valuable insights on the following aspects:
  1. Market Penetration: It provides comprehensive information about key players' market dynamics and offerings.
  2. Market Development: In-depth analysis of emerging markets and penetration across mature market segments, highlighting lucrative opportunities.
  3. Market Diversification: Detailed information about new product launches, untapped geographies, recent developments, and investments.
  4. Competitive Assessment & Intelligence: Exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of leading players.
  5. Product Development & Innovation: Intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
  1. What is the market size and forecast for the Chronic Myelogenous Leukemia Therapeutics Market?
  2. Which products, segments, applications, and areas hold the highest investment potential in the Chronic Myelogenous Leukemia Therapeutics Market?
  3. What is the competitive strategic window for identifying opportunities in the Chronic Myelogenous Leukemia Therapeutics Market?
  4. What are the latest technology trends and regulatory frameworks in the Chronic Myelogenous Leukemia Therapeutics Market?
  5. What is the market share of the leading vendors in the Chronic Myelogenous Leukemia Therapeutics Market?
  6. Which modes and strategic moves are suitable for entering the Chronic Myelogenous Leukemia Therapeutics Market?


Note: PDF & Excel + Online Access - 1 Year

Table of Contents

188 Pages
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Chronic Myelogenous Leukemia Therapeutics Market, by Region
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing number of diagnostic tests and predictive markers
5.1.1.2. Growing prevalence of chronic myelogenous leukemia
5.1.1.3. Rising awareness programs regarding chronic myeloid leukemia
5.1.2. Restraints
5.1.2.1. High cost of chronic myeloid leukemia treatment drugs
5.1.3. Opportunities
5.1.3.1. Increasing research and development activities for chronic myeloid leukemia treatment
5.1.3.2. Rising approval of drugs for treating chronic myelogenous leukemia
5.1.4. Challenges
5.1.4.1. Side effects and adverse reactions of chronic myeloid leukemia treatment
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization
6. Chronic Myelogenous Leukemia Therapeutics Market, by Tyrosine Kinase Inhibitors
6.1. Introduction
6.2. Antimetabolites
6.3. Asciminib
6.4. Bosutinib
6.5. Dasatinib
6.6. Nilotinib
6.7. Ponatinib
7. Chronic Myelogenous Leukemia Therapeutics Market, by Distribution Channel
7.1. Introduction
7.2. Hospital Pharmacies
7.3. Online Pharmacies
7.4. Retail Pharmacies
8. Americas Chronic Myelogenous Leukemia Therapeutics Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Chronic Myelogenous Leukemia Therapeutics Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Chronic Myelogenous Leukemia Therapeutics Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.2. Market Share Analysis, By Key Player
11.3. Competitive Scenario Analysis, By Key Player
12. Competitive Portfolio
12.1. Key Company Profiles
12.1.1. Abbvie Inc.
12.1.2. Amneal Pharmaceuticals LLC
12.1.3. Bristol Myers Squibb Company
12.1.4. F. Hoffmann La Roche Ltd.
12.1.5. Ilyang Pharmaceutical Co. Ltd.
12.1.6. Incyte Corporation
12.1.7. Innovent Biologics Inc.
12.1.8. Lupin Ltd.
12.1.9. Merck KGaA
12.1.10. Novartis AG
12.1.11. Pfizer Inc.
12.1.12. Sanofi S.A.
12.1.13. Sun Pharmaceutical Industries Ltd.
12.1.14. Takeda Pharmaceutical Co. Ltd.
12.1.15. Teva Pharmaceutical Industries Ltd.
12.1.16. Viatris Inc.
12.2. Key Product Portfolio
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us